Olivier Rixe

15.1k total citations · 2 hit papers
205 papers, 11.3k citations indexed

About

Olivier Rixe is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Olivier Rixe has authored 205 papers receiving a total of 11.3k indexed citations (citations by other indexed papers that have themselves been cited), including 110 papers in Oncology, 81 papers in Pulmonary and Respiratory Medicine and 68 papers in Molecular Biology. Recurrent topics in Olivier Rixe's work include Renal cell carcinoma treatment (34 papers), Cancer Treatment and Pharmacology (32 papers) and Lung Cancer Treatments and Mutations (24 papers). Olivier Rixe is often cited by papers focused on Renal cell carcinoma treatment (34 papers), Cancer Treatment and Pharmacology (32 papers) and Lung Cancer Treatments and Mutations (24 papers). Olivier Rixe collaborates with scholars based in France, United States and Canada. Olivier Rixe's co-authors include Stéphane Oudard, Robert J. Motzer, Ronald M. Bukowski, M. Dror Michaelson, Paul Bycott, Thomas E. Hutson, Robert A. Figlin, Piotr Tomczak, Charles M. Baum and Sindy T. Kim and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Olivier Rixe

193 papers receiving 11.1k citations

Hit Papers

align trajectories sort by overperformance

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma

2007 4.5k citations Robert J. Motzer, M. Dror Michaelson et al. profile →
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel

1996 510 citations Olivier Rixe et al. profile →

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author						Papers	Cites
Olivier Rixe	5.7k	5.3k	4.9k	2.8k	927	205	11.3k
Tim Eisen	7.0k 1.2×	7.4k 1.4×	4.4k 0.9×	4.1k 1.5×	875 0.9×	145	12.8k
Bohuslav Melichar	6.7k 1.2×	5.4k 1.0×	6.3k 1.3×	3.8k 1.4×	1.5k 1.6×	503	13.2k
Rebecca S. Heist	6.1k 1.1×	4.3k 0.8×	6.2k 1.3×	2.2k 0.8×	995 1.1×	268	11.6k
Balázs Halmos	7.6k 1.3×	4.9k 0.9×	8.0k 1.6×	2.2k 0.8×	672 0.7×	280	12.7k
Heather A. Wakelee	7.5k 1.3×	3.9k 0.7×	6.9k 1.4×	4.0k 1.4×	852 0.9×	447	13.5k
Justin F. Gainor	6.6k 1.2×	3.4k 0.6×	6.6k 1.3×	2.1k 0.7×	605 0.7×	235	10.6k
Sergio Bracarda	7.6k 1.3×	5.8k 1.1×	4.4k 0.9×	3.8k 1.4×	2.1k 2.2×	236	11.6k
Katsuyuki Kiura	8.2k 1.4×	3.9k 0.7×	7.6k 1.6×	1.9k 0.7×	818 0.9×	578	12.5k
Jin Seok Ahn	7.8k 1.4×	3.2k 0.6×	8.6k 1.8×	3.0k 1.1×	962 1.0×	452	13.5k
Malcolm Ranson	4.9k 0.9×	4.4k 0.8×	6.9k 1.4×	2.4k 0.9×	421 0.5×	181	11.4k

Countries citing papers authored by Olivier Rixe

Since Specialization

Citations

This map shows the geographic impact of Olivier Rixe's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olivier Rixe with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olivier Rixe more than expected).

Fields of papers citing papers by Olivier Rixe

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olivier Rixe. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olivier Rixe. The network helps show where Olivier Rixe may publish in the future.

Co-authorship network of co-authors of Olivier Rixe

This figure shows the co-authorship network connecting the top 25 collaborators of Olivier Rixe. A scholar is included among the top collaborators of Olivier Rixe based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olivier Rixe. Olivier Rixe is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Yap, Timothy A., Olivier Rixe, Capucine Baldini, et al.. (2025). First‐in‐human phase 1 study of KHK2455 monotherapy and in combination with mogamulizumab in patients with advanced solid tumors. Cancer. 131(13). e35939–e35939. 2 indexed citations

Rixe, Olivier, John L. Villano, Robert Wesolowski, et al.. (2024). A First-in-Human Phase I Study of BXQ-350, a First-in-Class Sphingolipid Metabolism Regulator, in Patients with Advanced/Recurrent Solid Tumors or High-Grade Gliomas. Clinical Cancer Research. 30(22). 5053–5060. 1 indexed citations

Davar, Diwakar, Roberta Zappasodi, Hong Wang, et al.. (2022). Phase IB Study of GITR Agonist Antibody TRX518 Singly and in Combination with Gemcitabine, Pembrolizumab, or Nivolumab in Patients with Advanced Solid Tumors. Clinical Cancer Research. 28(18). 3990–4002. 37 indexed citations

Zakharia, Yousef, et al.. (2015). Axitinib: from preclinical development to future clinical perspectives in renal cell carcinoma. Expert Opinion on Drug Discovery. 10(8). 925–935. 9 indexed citations

Sarantopoulos, John, Alain C. Mita, James L. Wade, et al.. (2014). Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel. Cancer Chemotherapy and Pharmacology. 74(6). 1113–1124. 12 indexed citations

Rini, Brian I., May Garrett, Bill Poland, et al.. (2013). Axitinib in Metastatic Renal Cell Carcinoma: Results of a Pharmacokinetic and Pharmacodynamic Analysis. The Journal of Clinical Pharmacology. 53(5). 491–504. 117 indexed citations

Fruehauf, John P., Jose Lutzky, David H. McDermott, et al.. (2011). Multicenter, Phase II Study of Axitinib, a Selective Second-Generation Inhibitor of Vascular Endothelial Growth Factor Receptors 1, 2, and 3, in Patients with Metastatic Melanoma. Clinical Cancer Research. 17(23). 7462–7469. 93 indexed citations

Beuselinck, Benoit, Stéphane Oudard, Olivier Rixe, et al.. (2010). Negative impact of bone metastasis on outcome in clear-cell renal cell carcinoma treated with sunitinib. Annals of Oncology. 22(4). 794–800. 115 indexed citations

Oudard, Stéphane, Olivier Rixe, Benoit Beuselinck, et al.. (2010). A phase II study of the cancer vaccine TG4010 alone and in combination with cytokines in patients with metastatic renal clear-cell carcinoma: clinical and immunological findings. Cancer Immunology Immunotherapy. 60(2). 261–271. 71 indexed citations

10.

Rixe, Olivier, Sandra Franco, Denise A. Yardley, et al.. (2009). A randomized, phase II, dose-finding study of the pan-ErbB receptor tyrosine-kinase inhibitor CI-1033 in patients with pretreated metastatic breast cancer. Cancer Chemotherapy and Pharmacology. 64(6). 1139–1148. 43 indexed citations

11.

Rixe, Olivier, Ronald M. Bukowski, M. Dror Michaelson, et al.. (2007). Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. The Lancet Oncology. 8(11). 975–984. 356 indexed citations

12.

Rottey, Sylvie, Ken A. Olaussen, Jean‐Charles Soria, et al.. (2006). Cyclooxygenase-2 as a target for anticancer drug development. Critical Reviews in Oncology/Hematology. 59(1). 51–64. 172 indexed citations

13.

Spano, Jean‐Philippe, Jacques‐Olivier Bay, Jean‐Yves Blay, & Olivier Rixe. (2005). L’inhibition du protéasome : une nouvelle approche thérapeutique en onco-hématologie. Bulletin du Cancer. 92(11). 945–952. 5 indexed citations

14.

Spano, Jean‐Philippe, Rémi Fagard, Jean‐Charles Soria, et al.. (2005). Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Annals of Oncology. 16(2). 189–194. 156 indexed citations

15.

Cals, L., Olivier Rixe, Éric François, et al.. (2004). Dose-finding study of weekly 24-h continuous infusion of 5-fluorouracil associated with alternating oxaliplatin or irinotecan in advanced colorectal cancer patients. Annals of Oncology. 15(7). 1018–1024. 23 indexed citations

16.

Raymond, Éric, Michel Fabbro, Valérie Boige, et al.. (2003). Multicentre phase II study and pharmacokinetic analysis of irinotecan in chemotherapy-naïve patients with glioblastoma. Annals of Oncology. 14(4). 603–614. 67 indexed citations

17.

Khayat, David, Olivier Rixe, G. Martin, et al.. (2003). Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1‐mm thick). Cancer. 97(8). 1941–1946. 171 indexed citations

18.

Monnet, I., Hubert de Crémoux, P Soulié, et al.. (2002). Oxaliplatin plus vinorelbine in advanced non-small-cell lung cancer: final results of a multicenter phase II study. Annals of Oncology. 13(1). 103–107. 31 indexed citations

19.

Soria, Jean‐Charles & Olivier Rixe. (1997). Télomères, télomérase et cancer. Bulletin du Cancer. 84(10). 0–0.

20.

Petit, Thierry, Christian Borel, Olivier Rixe, et al.. (1996). Complete remission seven years after treatment for metastatic malignant melanoma. Cancer. 77(5). 900–902. 15 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact